TP53 and ovarian carcinoma: PRIMA-1 (p53 reactivation and induction of massive apoptosis) and its methylated form PRIMA-1MET are small molecules capable of converting mutant p53 to active wild type conformation and have been shown to overcome drug resistance in ovarian cancer cells [48,49].